Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, takes a ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

A retrospective review shows that dermatologic patients treated with mycophenolate mofetil face a significantly lower incidence of malignancy than transplant recipients.

-- For many of these favored stocks, the share prices are close to the consensus price targets, or even exceed them. Most analysts set 12-month price targets. So we made one more cut to 15 stocks for ...